IMR Press / FBL / Volume 26 / Issue 4 / DOI: 10.2741/4914

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Role of cyclooxygenase-2 in colorectal cancer
Show Less
1 The Sol Goldman Pancreatic Cancer Research Center, Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
2 Department of Biophysics, Panjab University, Chandigarh, 160014, India
Send correspondence to: Devinder Kumar Dhawan, Department of Biophysics, Panjab University, Chandigarh-160014, India,Tel.: 91-172-2534121, Fax: 91-172-2541022, E-mail:
Front. Biosci. (Landmark Ed) 2021, 26(4), 706–716;
Published: 1 October 2020

Cyclooxygenase-2 (COX-2) is an inducible enzyme which triggers the biosynthesis of prostaglandins. COX-2 is activated in response to inflammatory stimuli and is one of the major molecules that is involved in the development and progression of colorectal cancer (CRC). Consistent with such a conceptual framework, it has been shown that COX-2 inhibitors prevent the carcinogenesis of CRC and aid in the treatment of sporadic or familial cases of CRC as shown by an overall increase in the survival rate. However, prolonged use of these inhibitors is associated with increase risk of development of cardiovascular complications, implying that further research is required to identify COX-2 inhibitors that are associated with lower risks of such complications.

Colorectal cancer
Figure 1
Back to top